Recombinant erythropoietin (Cadila Pharmaceuticals)
重组人促红素（Cadila Pharmaceuticals）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant erythropoietin (Cadila Pharmaceuticals)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCadila Pharmaceuticals Ltd
China Registration ClassN/A
Develop Information
Active CompaniesZydus Lifesciences Ltd
Inactive CompaniesCadila Pharnmaceuticals
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A